|
|
|
| Clinical Effect of Drug-Eluting Balloon in the Treatment of ISR after PCI in Patients with Coronary Heart Disease |
| ZOU Yong-wei, HU Xiao-lian |
| The Second People’s Hospital of Hainan ,Wuzhishan, Hainan Province,572299 |
|
|
|
Abstract 【Objective】To study the clinical effect of drug-eluting balloon (DEB) in the treatment of ISR after percutaneous coronary intervention (PCI) in patients with coronary heart disease.【Methods】The clinical data of 50 patients with coronary heart disease treated by ISR from January 2012 to May 2017 were analyzed retrospectively. According to the type of stent, it was divided into DES group and DEB group. The clinical features, coronary angiography features, and terminal events within 12 months after treatment were compared between the two groups.【Results】After 6 months of treatment, coronary angiography showed that the incidence of restenosis in the DEB group was significantly lower than that in the DES group (P<0.05).There was no significant difference in TIMI blood flow grade Ⅰ, Ⅱ, Ⅲ, stenosis degree, minimum lumen diameter and late lumen loss between the two groups (P>0.05). The incidence of secondary stent stenosis in the DES group was 24.00% (6 / 25), which was significantly higher than that in the DEB group (4.00%, 1 / 25). The difference was statistically significant(χ2=4.153,P=0.042<0.05). Kaplan-Meier survival analysis showed that there was no significant difference in MACE free survival rate between the two groups within 12 months after operation (χ2=0.467,P=0.494＞0.05). 【Conclusion】The clinical efficacy of DEB in the treatment of ISR is comparable to that of DES with high safety, and no serious complications such as artery laceration dissection have been caused.
|
|
Received: 01 June 2018
|
|
|
|
|
|
[1] Byrne RA,Neumann FJ,Mehilli J,et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial[J].Lancet,2013,381(9865):461-467.
[2] 曾书燚,王正东,陈 坚,等. 药物洗脱球囊与药物洗脱支架治疗支架内再狭窄疗效比较[J].介入放射学杂志,2017,26(9):839-842.
[3] 王志胜,郭成军.药物洗脱球囊在冠状动脉粥样硬化性心脏病 介入治疗中的应用进展[J].中国医药,2016,11(2):290-292.
[4] 王悦喜,阿荣,任保军,等. 70岁以上冠心病患者支架植入术后影响预后因素[J].中华老年医学杂志,2012,31(2):110-112.
[5] Kastrati A,Baldus S,Cremer J,et al.Comments on the 2014 ESC/EACTS guidelines on myocardial revascularization of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery (EACTS) [J].Der Kardiologe,2016,10(6):359-370.
[6] Drachman DE, Simon DI..Inflammation as a mechanism and therapeutic target for in-stent restenosis[J].Curr Atheroscler Rep,2005,7(1):44-49.
[7] Rittger H,Brachmann J,Sinha AM,et al.A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study [J].J Am Coll Cardiol,2012,59(15):1377-1382.
[8] Habara S,Kadota K,Kanazawa T,et al.Paclitaxel-coated balloon catheter compared with drug-eluting stent for drug-eluting stent restenosis in routine clinical practice [J].EuroIntervention,2016,11(10):1098-1105. |
|
|
|
2018, Vol. 35 
